**Supplementary Table S1.**

Prognostic capability of FAM115C on the overall survival of 185 PDAC patients from the publicly available TCGA-PAAD dataset.

| variable | P value |
|----------|---------|
| 20%      | 0.075   |
| 25%      | 0.148   |
| 30%      | 0.321   |
| 35%      | 0.139   |
| 40%      | 0.146   |
| 42%      | 0.0463* |
| 45%      | 0.208   |
| 50%      | 0.186   |
| 55%      | 0.274   |
| 60%      | 0.261   |
| 65%      | 0.507   |
| 70%      | 0.781   |
| 75%      | 0.959   |
| 80%      | 0.520   |

*Significant difference

At the cutoff point of 42% for the separation of the high and low FAM115C expression group, high FAM115C expression is correlated with good prognosis of overall survival. P value; log-rank test.
**Supplementary Table S2.**

Prognostic capability of FAM115C on the disease/progression-free survival of 141 PDAC patients from the publicly available TCGA-PAAD dataset.

| variable | P value |
|----------|---------|
| 20%      | 0.274   |
| 25%      | 0.156   |
| 30%      | 0.196   |
| 35%      | 0.033*  |
| 40%      | 0.039*  |
| 41%      | 0.029*  |
| 45%      | 0.207   |
| 50%      | 0.398   |
| 55%      | 0.222   |
| 60%      | 0.497   |
| 65%      | 0.986   |
| 70%      | 0.853   |
| 75%      | 0.934   |
| 80%      | 0.443   |

*Significant difference

At the cutoff point of 41% for the separation of the high and low FAM115C expression group, high FAM115C expression is correlated with good prognosis of disease/progression-free survival. P value; log-rank test.
**Supplementary Table S3.**

Prognostic capability of FAM115C on the overall survival of 62 pancreatic cancer patients treated at our institution.

| variable | P value |
|----------|---------|
| 20%      | 0.1898  |
| 25%      | 0.1115  |
| 30%      | 0.0799  |
| 35%      | 0.2094  |
| 40%      | 0.0954  |
| 45%      | 0.0303* |
| 50%      | 0.1894  |
| 55%      | 0.1094  |
| 60%      | 0.2089  |
| 65%      | 0.3357  |
| 70%      | 0.0741  |
| 75%      | 0.0461* |
| 80%      | 0.1574  |

*Significant difference

At the cutoff point of 45% for the separation of the high and low FAM115C expression group, high FAM115C expression is correlated with good prognosis of overall survival. P value; generalized Wilcoxon test.
Supplementary Table S4.

Prognostic capability of FAM115C on the disease-free survival of 62 pancreatic cancer patients treated at our institution.

| variable | P value  |
|----------|----------|
| 20%      | 0.6693   |
| 25%      | 0.2766   |
| 30%      | 0.1623   |
| 35%      | 0.3507   |
| 40%      | 0.1547   |
| 45%      | 0.0384*  |
| 50%      | 0.2106   |
| 55%      | 0.1707   |
| 60%      | 0.3516   |
| 65%      | 0.6277   |
| 70%      | 0.2103   |
| 75%      | 0.1922   |
| 80%      | 0.0363*  |

*Significant difference

At the cutoff point of 45% for the separation of the high and low FAM115C expression group, high FAM115C expression is correlated with good prognosis of disease-free survival. P value; generalized Wilcoxon test.